Do you test your esophageal and gastric specimens for Her2 using IHC, FISH, or both?
What other molecular tests do you routinely order on such tumors?
Answer from: Medical Oncologist at Academic Institution
Per ASCO and College of American Pathology guidelines, we start with IHC. For tumors that are IHC 0/1+ (negative) or 3+ (positive), no further testing is indicated. For IHC 2+ tumors, we then proceed to FISH. IHC 2+ and FISH +ve tumors and IHC 3+ tumors are offered trastuzumab in the metastatic sett...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Our typical approach is to do Her2 IHC and FISH in all new esophageal/gastric adenocarcinoma cases. We also routinely test PDL1 (by CPS), MSI, and TMB. Most patients will also have tumor sent for genomic profiling. In that context, Her2 mutations and ERBB2 will usually be assessed, but our initial d...
Answer from: Medical Oncologist at Community Practice
With the advances in HER-2 directed therapies and availability of novel antibody drug conjugates (ADC), numerous issues are emerging that need to be addressed to optimize the HER-2 testing beyond what we have today. Assessment of low HER-2 expression now has become an important issue. The definition...
Answer from: Medical Oncologist at Community Practice
Both IHC and FISH